ERBB2 and gastroesophageal junction adenocarcinoma: For this reason, Estephan and colleagues recently evaluated HER2 expression in PC through the HER2 scoring system used for gastric and gastroesophageal junction adenocarcinoma, reporting HER2 positivity in 23% of neoplasms [121].